InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,813.67
(
-0.33%
)
US TECH 100
19,650.80
(
-1.03%
)
Dow Jones
42,141.54
(
-0.22%
)
Brent Oil
72.33
(
-0.41%
)
Bitcoin
72,303.30
(
-0.05%
)
Post# of 29633
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120640
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 29622

Wednesday, 10/16/2024 1:01:14 PM

Wednesday, October 16, 2024 1:01:14 PM

Post# of 29633
ABT 3Q24 Results by Business Segment 
  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  45%       +13% 
 Diagnostics       23%        +1%† 
 Nutrition         19%        +8% 
 Pharmaceuticals‡  13%        +7%
60% of overall corporate sales were ex-US.

*Includes diabetes care.
‡Branded generics and biosimilars in emerging markets.

†Excluding COVID diagnostics, 3Q24 diagnostics sales were +3% YoY in constant currency. (COVID-diagnostics sales were $265M in 3Q24 vs $305M in 3Q23.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up